Abstract
The Major Histocompatibility Complex Class II locus is the primary genetic linkage to autoimmune diseases. Susceptibility to each such disease is linked to different alleles, with a few alleles showing also dominant protection. The design of vaccines for autoimmune diseases is a long sought-after goal. As knowledge about the pathogenesis of these diseases has increased, the tools for such an approach have of necessity been refined. We review below the structural essence of MHC II-linked autoimmune diseases which centers on the binding of antigenic peptides to the disease-linked MHC II proteins, and the consequent activation of cognate TCRs from pathogenic CD4+ T cells. The state of affairs in two organ-specific autoimmune diseases, type 1 diabetes, celiac disease are covered, including attempts to treat these via antigen-specific MHC II-guided measures. We offer a couple of testable suggestions as to how this approach could be improved.
Keywords: APL, autoimmunity, HLA, MHC, vaccines
Current Pharmaceutical Design
Title: Use of MHC II Structural Features in the Design of Vaccines for Organ-Specific Autoimmune Diseases
Volume: 15 Issue: 28
Author(s): Antonis K. Moustakas and George K. Papadopoulos
Affiliation:
Keywords: APL, autoimmunity, HLA, MHC, vaccines
Abstract: The Major Histocompatibility Complex Class II locus is the primary genetic linkage to autoimmune diseases. Susceptibility to each such disease is linked to different alleles, with a few alleles showing also dominant protection. The design of vaccines for autoimmune diseases is a long sought-after goal. As knowledge about the pathogenesis of these diseases has increased, the tools for such an approach have of necessity been refined. We review below the structural essence of MHC II-linked autoimmune diseases which centers on the binding of antigenic peptides to the disease-linked MHC II proteins, and the consequent activation of cognate TCRs from pathogenic CD4+ T cells. The state of affairs in two organ-specific autoimmune diseases, type 1 diabetes, celiac disease are covered, including attempts to treat these via antigen-specific MHC II-guided measures. We offer a couple of testable suggestions as to how this approach could be improved.
Export Options
About this article
Cite this article as:
Moustakas K. Antonis and Papadopoulos K. George, Use of MHC II Structural Features in the Design of Vaccines for Organ-Specific Autoimmune Diseases, Current Pharmaceutical Design 2009; 15 (28) . https://dx.doi.org/10.2174/138161209789105117
DOI https://dx.doi.org/10.2174/138161209789105117 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Monoclonal Antibodies: A Review
Current Clinical Pharmacology Recent Clinical Trials of Cladribine in Hematological Malignancies and Autoimmune Disorders
Reviews on Recent Clinical Trials Vitamin D Receptor as a Drug Discovery Target
Mini-Reviews in Medicinal Chemistry Biologics as Treatment for Systemic Lupus: Great Efforts, Sobering Results, New Challenges
Current Drug Discovery Technologies Endothelial Chemokines in Autoimmune Disease
Current Pharmaceutical Design “Something is Wrong in the Ras Kingdom” - Evidence for the Involvement of p21Ras/MAP Kinase in Autoimmune Diseases
Current Rheumatology Reviews Genetics and Ulcerative Colitis: What are the Clinical Implications?
Current Drug Targets Chronic Inflammation and Oxidative Stress as a Major Cause of Age- Related Diseases and Cancer
Recent Patents on Inflammation & Allergy Drug Discovery Autoantibody-Induced Formation of Immune Complexes in Normal Human Serum
Current Pharmaceutical Design Immunology Behind Tumors: A Mini Review
Current Cancer Therapy Reviews Oral Agents in Multiple Sclerosis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Monocyte Dependent Regulation of Autoimmune Inflammation
Current Molecular Medicine Chitosan Nanoparticles: A Therapeutic Carrier for Delivery of DNA, siRNA and CpG-ODNs
Nanoscience & Nanotechnology-Asia Somatic Genome Variations in Health and Disease
Current Genomics Autoimmune Diseases and Atherosclerosis: The Inflammatory Connection
Current Immunology Reviews (Discontinued) Defensive and Offensive Cross-Reactive Antibodies Elicited by Pathogens: The Good, the Bad and the Ugly
Current Medicinal Chemistry Local Treatment for Lymphoid Malignancies of the Eye
Anti-Cancer Agents in Medicinal Chemistry Targeting T-Cell Adhesion Molecules for Drug Design
Current Pharmaceutical Design Modulation of TNF Receptor Family Members to Inhibit Autoimmune Disease
Current Drug Targets - Inflammation & Allergy Novel Carriers for Coenzyme Q10 Delivery
Current Drug Delivery